Fabrication and Characterization of Surface Engineered Rifampicin Loaded Lipid Nanoparticulate Systems for the Potential Treatment of Tuberculosis: An In Vitro and In Vivo Evaluation

Chokshi, Nimitt V; Rawal, Shruti; Solanki, Dhruvi; Gajjar, Saumitra; Bora, Vivek; Patel, Bhoomika M.; Patel, Mayur M.

doi:10.1016/j.xphs.2021.02.018

Cited by 15 publications

(3 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentrations of rifampicin in various processed organs were detected by high-performance liquid chromatography (HPLC) as reported previously with some changes [36,37].…”

Section: In Vivo Biodistribution Studiesmentioning

confidence: 92%

A novel synergistic enzyme-Antibiotic Therapy with Immobilization of Mycobacteriophage LysinB enzyme onto Rif@UiO-66 Nanocomposite for Enhanced Anti-TB Nanotherapeutic; Nanoenzybiotics approach

Eldin,

Dishisha,

Sayed

et al. 2023

Preprint

View full text Add to dashboard Cite

The emergence of antibiotic-resistant and phage-resistant strains of Mycobacterium tuberculosis (M. tuberculosis) necessitates improving new therapeutic plans. The objective of the current work was to ensure the effectiveness of rifampin and the mycobacteriophage LysB D29 enzyme in the treatment of MDR-TB infection, where new and safe metal–organic framework (MOF) nanoparticles were used in combination. UiO-66 nanoparticles were synthesized under mild conditions in which the antimycobacterial agent (rifimpacin) was loaded (Rif@UiO-66) and LysB D29 enzyme immobilized onto Rif@UiO-66, which were further characterized. Subsequently, the antibacterial activity of different ratios of Rif@UiO-66 and LysB/Rif@uio-66 against the nonpathogenic tuberculosis model Mycobacterium smegmatis (M. smegmatis) was evaluated by minimum inhibitory concentration (MIC) tests. Impressively, the MIC of LysB/Rif@uio-66 was 16-fold lower than that of pure rifampicin. In vitro and in vivo toxicity studies proved that LysB/Rif@UiO-66 is a highly biocompatible therapy for pulmonary infection. A biodistribution assay showed that LysB/Rif@UiO-66 showed a 5.31-fold higher drug concentration in the lungs than free rifampicin. A synergistic interaction between UiO-66, rifampicin and the mycobacteriophage lysB D29 enzyme was shown in the computational method (docking). Therefore, all results indicated that the LysB/Rif@UiO-66 nanocomposite exhibited promising innovative enzyme-antibiotic therapy for tuberculosis treatment.

show abstract

“…The concentrations of rifampicin in various processed organs were detected by high-performance liquid chromatography (HPLC) as reported previously with some changes [36,37].…”

Section: In Vivo Biodistribution Studiesmentioning

confidence: 92%

A novel synergistic enzyme-Antibiotic Therapy with Immobilization of Mycobacteriophage LysinB enzyme onto Rif@UiO-66 Nanocomposite for Enhanced Anti-TB Nanotherapeutic; Nanoenzybiotics approach

Eldin,

Dishisha,

Sayed

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Consequently, the formulation was considered effective in delivering drugs to the peripheral respiratory tract. Chokshi et al [103] have prepared mannose-appended rifampicin containing solid lipid nanoparticles (Mn-RIF-SLNs) for the management of pulmonary TB. Cytotoxicity studies using the J774A.1-cell line have shown that the developed Mn-RIF-SLNs, as compared with free drugs, are nontoxic and biocompatible.…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 99%

Advances in therapeutic nanodrug delivery systems for infectious lung diseases: a review

Sheng

Tian

Duan

et al. 2022

Acta Materia Medica

View full text Add to dashboard Cite

Infectious lung diseases are inflammatory diseases of the lungs caused by infectious agents such as bacteria, viruses or fungi. Oral or intravenous administration of antibiotics is the most common method of treatment, but some drugs have poor release stability, high systemic toxicity and susceptibility to drug resistance. Nanodrug delivery systems are promising alternatives for the treatment of infectious lung diseases, because they provide the advantages of enhancing the stability and solubility of delivered drugs, increasing pulmonary accumulation, decreasing systemic toxicity and ameliorating drug resistance. This review provides a brief overview of recent advances in approaches and ideas in pulmonary drug delivery methods. We believe that nano-based therapeutic strategies offer great potential to broaden the scope of treatment of infectious lung diseases and enhance therapeutic efficacy.

show abstract

“…The study performed by Chokshi et al (2018) 18 also exhibited improved gastrointestinal stability of rifampicin in rifampicinloaded solid lipid nanoparticles. Also, Chokshi et al (2021) 19 showed that the mannose-appended rifampicin containing solid lipid nanoparticles exhibited high relative bioavailability and high lung deposition compared to that of the free drug and without mannose nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

Enhancement of Antimycobacterial Activity of Rifampicin Using Mannose-Anchored Lipid Nanoparticles against Intramacrophage Mycobacteria

Mistry

Bandyopadhyaya

Mehra

2022

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Tuberculosis treatment requires a multidrug combination for the long-term, associated with adverse effects which lead to nonpatient compliance and the emergence of drug-resistant strains. Thus, mannose-anchored rifampicin-loaded solid lipid nanoparticles (M-RIF-SLNs) were developed to enhance the effect of rifampicin by selectively delivering to the macrophage, which led to the high intracellular killing of mycobacteria. The synthesized M-RIF-SLNs show a particle size of ∼100 nm and a drug loading of ∼8%. Cytotoxicity assay confirms that M-RIF-SLNs are not toxic up to 16 μg/mL (equivalent to incorporated rifampicin in SLN) toward THP-1differentiated macrophages. An antimicrobial assay exhibits a reduction of minimum inhibitory concentration by 4-fold and 8-fold against wildtype and laboratory drug-resistant strains of M. smegmatis, respectively, compared to free rifampicin. Furthermore, mannose-functionalized SLNs loaded with coumarin-6 exhibit a higher macrophage uptake than that of unfunctionalized SLNs. Finally, higher intramacrophage clearance of M. tuberculosis H37Ra was observed with M-RIF-SLNs compared to RIF-SLNs and free rifampicin. Hence, the overall results support that the developed M-RIF-SLNs can be a promising approach for improving the antibacterial activity of rifampicin against intracellular mycobacteria residing in the alveolar macrophages.

show abstract

Fabrication and Characterization of Surface Engineered Rifampicin Loaded Lipid Nanoparticulate Systems for the Potential Treatment of Tuberculosis: An In Vitro and In Vivo Evaluation

Cited by 15 publications

References 74 publications

A novel synergistic enzyme-Antibiotic Therapy with Immobilization of Mycobacteriophage LysinB enzyme onto Rif@UiO-66 Nanocomposite for Enhanced Anti-TB Nanotherapeutic; Nanoenzybiotics approach

A novel synergistic enzyme-Antibiotic Therapy with Immobilization of Mycobacteriophage LysinB enzyme onto Rif@UiO-66 Nanocomposite for Enhanced Anti-TB Nanotherapeutic; Nanoenzybiotics approach

Advances in therapeutic nanodrug delivery systems for infectious lung diseases: a review

Enhancement of Antimycobacterial Activity of Rifampicin Using Mannose-Anchored Lipid Nanoparticles against Intramacrophage Mycobacteria

Contact Info

Product

Resources

About